PCRX
Pacira BioSciences, Inc. · Healthcare
Insiders sold $2.0M of Pacira BioSciences, Inc. in the last 12 months and bought none
PCRX over the last year
PCRX after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
193 insider filings since 2016, newest first
Lauren Bullaro Riker · SVP, Finance
Kristen Marie Williams · Chief Administrative Officer
Mark Froimson · Director
Max Reinhardt · Pres, Rest of World
Max Reinhardt · Pres, Rest of World
Anthony Molloy · Chief Lgl, Compliance Officer
Kristen Marie Williams · Chief Administrative Officer
Lauren Bullaro Riker · SVP, Finance
John P Phd Longenecker · Director
Gary W Pace · Director
Kristen Marie Williams · Chief Administrative Officer
Kristen Marie Williams · Chief Administrative Officer
Lauren Bullaro Riker · SVP, Finance
Kristen Marie Williams · Chief Administrative Officer
Lauren Bullaro Riker · VP, Finance
Max Reinhardt · Pres, Rest of World
Kristen Marie Williams · Chief Administrative Officer
Lauren Bullaro Riker · VP, Finance
Donald C. Manning · Chief Medical Officer
Roy Winston · Chief Clinical Officer
David M Stack · CEO and Chair
Charles A. Reinhart III · CFO
Max Reinhardt · Pres, Rest of World
Dennis Mcloughlin · Chief Customer Officer
Charles Anthony Laranjeira · Chief Technical Officer
Paul J Hastings · Director
Lauren Bullaro Riker · VP, Finance
Kristen Marie Williams · Chief Administrative Officer
Donald C. Manning · Chief Medical Officer
David M Stack · CEO and Chair
Kristen Marie Williams · Chief Administrative Officer
Roy Winston · Chief Clinical Officer
Mark Froimson · Director
Lauren Bullaro Riker · VP, Finance
Andreas Wicki · Director
Andreas Wicki · Director
Paul J Hastings · Director
John P Phd Longenecker · Director
David M Stack · CEO and Chair
Laura Brege · Director
Roy Winston · Chief Clinical Officer
Max Reinhardt · President
Lauren Bullaro Riker · VP, Finance
David M Stack · CEO and Chair
Max Reinhardt · President
Lauren Bullaro Riker · VP, Finance
Kristen Marie Williams · Chief Administrative Officer
Andreas Wicki · Director
David M Stack · CEO and Chair
Andreas Wicki · Director
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.